Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198

NCT02581215 is registered in ClinicalTrials.gov with Walid Shaib, MD as lead sponsor.

NCT NCT02581215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Lead sponsor
Walid Shaib, MD
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2016
Completion date
January 27, 2022
Enrollment
84 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer